// App-Quantinova.ai

P3-08-01 : MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors

Researchers

Presenter

  • Patrick Neven

Principal Investigators

  • Stephen Johnston

  • Masakazu Toi

  • Joohyuk Sohn

  • Kenichi Inoue

  • Xavier Pivot

  • Olga Burdaeva

  • Meena Okera

  • Norikazu Masuda

  • Peter A Kaufman

  • Han Koh

  • Eva-Maria Grischke

  • PierFranco Conte

  • Yi Lu

  • Nadine Haddad

  • Karla Hurt

  • Antonio Llombart-Cussac

  • George W Sledge, Jr

Medical Centers

  • Universitaire Ziekenhuizen Leuven, Leuven, Belgium

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Graduate School of Medicine Kyoto University, Kyoto, Japan

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)

  • Saitama Cancer Center, Ina, Japan

  • Centre Paul Strauss, Strasbourg, France

  • Arkhangelsk Regional Clinical Oncologic Dispensary, Arkhangelsk, Russia

  • Adelaide Cancer Centre, Adelaide, Australia

  • Osaka National Hospital, Osaka, Japan

  • University of Vermont Medical Center, Burlington, VT

  • Kaiser Permanente, Bellflower, CA

  • Universitts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany

  • University of Padova and Istituto Oncologico Veneto IOV IRCCS, Padova, Italy

  • Eli Lilly and Company, Indianapolis, IN

  • Hospital Arnau Vilanova, Valencia, Spain

Locations

  • Belgium

  • United Kingdom

  • Japan

  • Republic of South Korea

  • France

  • Russia

  • Australia

  • United States

  • Germany

  • Italy

  • Spain

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Abemaciclib

  • Fulvestrant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02107703

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved